openPR Logo
Press release

FibroGen's Pamrevlumab market size expected to increase many folds by 2032, report DelveInsight

02-12-2024 01:23 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

DelveInsight has recently published a report on "Pamrevlumab Market Forecast Report" providing an in-depth analysis of the Pamrevlumab market analysis and forecasts up to 2032 in the seven major markets (7MM) (i.e. the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The comprehensive report provides an analysis of Pamrevlumab market potential and market share analysis in the Idiopathic Pulmonary Fibrosis therapeutics space across the 7MM from 2019 to 2032.

The report also helps you to understand the Pamrevlumab clinical and commercial developments along with parameters like the drug's Mechanism of Action (MOA), Route of Administration (ROA), dosage, and special designations.

Interested in finding out the projected market size of Pamrevlumab by 2032? Visit Pamrevlumab Market Forecast @https://www.delveinsight.com/report-store/pamrevlumab-ipf-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=druginsightpr&utm_campaign=kpr

Pamrevlumab Drug Summary

FibroGen is in the process of developing pamrevlumab (also referred to as FG-3019), a first-in-class, fully-humanized monoclonal antibody administered intravenously. This innovative antibody effectively inhibits the activity of connective tissue growth factor (CTGF), a pivotal mediator in the progression of fibrosis and associated serious diseases.

Following the successful completion of the Phase II clinical study, FibroGen is now advancing pamrevlumab into Phase III clinical development for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The company is currently conducting two Phase III studies of pamrevlumab in IPF, employing a randomized, double-blind, placebo-controlled design. Each study in the United States has a primary efficacy endpoint focused on the change from baseline in forced vital capacity (FVC). In Europe, the primary efficacy endpoint is defined by disease progression, indicated by a decline in FVC percent predicted of equal to or greater than 10%, or death. Secondary endpoints encompass clinical outcomes related to disease progression, acute IPF exacerbations, patient-reported outcomes, and quantitative changes in lung fibrosis volume from baseline. The enrollment for the ZEPHYRUS-1 trial, the initial Phase III trial involving 356 IPF patients, has been completed. Simultaneously, FibroGen is actively enrolling patients in ZEPHYRUS-2, the second Phase III trial featuring approximately 340 IPF patients.

Beyond IPF, FibroGen is exploring pamrevlumab in Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD) and locally advanced unresectable pancreatic cancer (LAPC). Notably, the drug has shown potential in stabilizing disease and reversing lung fibrosis in certain patients, as reported by the company.

According to FibroGen's latest updates, the topline data from the ZEPHYRUS-1 Phase III study of pamrevlumab in IPF is anticipated in mid-2023.

Stay ahead of the competition by leveraging key insights and evolving trends in the Pamrevlumab Market Pamrevlumab Market Outlook and Key Assessment @ https://www.delveinsight.com/sample-request/pamrevlumab-ipf-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=druginsightpr&utm_campaign=kpr

Key Highlights of the Pamrevlumab Market Report

The report contains forecasted sales evaluation of Pamrevlumab for Idiopathic Pulmonary Fibrosis till 2032.
It provides comprehensive coverage of late-stage emerging therapies for Idiopathic Pulmonary Fibrosis treatment.
The report also features qualitative and quantitative analysis with analysts, as well as KOL views for Pamrevlumab in Idiopathic Pulmonary Fibrosis.

Why Pamrevlumab Market Report?

Leading Pamrevlumab for Idiopathic Pulmonary Fibrosis forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Pamrevlumab.

A thorough Pamrevlumab market forecast will help understand how the drug is competing with other emerging therapies in the therapeutics landscape.

It will help to get an analysis of the Pamrevlumab clinical trial advancements and the detailed clinical assessment, regulatory, and commercial assessment.

The report also provides future market assessments for Pamrevlumab market for Idiopathic Pulmonary Fibrosis in the 7 Major Markets, advanced qualitative analysis like SWOT, expert analysts' views, a detailed overview of market competitors, and a short analysis of other emerging therapies in Idiopathic Pulmonary Fibrosis.

Download the sample report to learn more about the evolving market dynamics Pamrevlumab Market Trends and Key Developments @ https://www.delveinsight.com/sample-request/pamrevlumab-ipf-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=druginsightpr&utm_campaign=kpr

Related Reports By DelveInsight:

Idiopathic Pulmonary Fibrosis Market Outlook and Forecast
"Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology and Market Forecast 2032" report delivers an in-depth understanding of Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan. It also covers the key companies and emerging therapies in the Idiopathic Pulmonary Fibrosis therapeutics landscape.

Top Services Offered By DelveInsight:

Elevate healthcare strategies with Delveinsight Healthcare Consulting. Unlock insights, navigate challenges, and drive success in the dynamic healthcare landscape. https://www.delveinsight.com/consulting

Explore success with our case study on R&D, Manufacturing & Commercial Capabilities. Uncover insights for strategic growth in the industry. https://www.delveinsight.com/case-study/r-and-d-landscape-assessment

Unlock success with our Product Assessment case study. Gain valuable insights for strategic decision-making and product optimization in your industry. https://www.delveinsight.com/case-study/oncology-product-assessment-dashboard

Elevate your business with our Market Assessment case study. Transform insights into strategic actions for success in your industry. https://www.delveinsight.com/case-study/immune-checkpoint-inhibitor-market-potential

428, Corporate Park, Sector-21, Dwarka,
New Delhi-110077, India

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release FibroGen's Pamrevlumab market size expected to increase many folds by 2032, report DelveInsight here

News-ID: 3381385 • Views:

More Releases from DelveInsight Business Research LLP

Tirzepatide Market Size and Share Across 7MM and Competitive Landscape by DelveInsight | Key Players - Eli Lilly and Company
Tirzepatide Market Size and Share Across 7MM and Competitive Landscape by DelveI …
DelveInsight has released a comprehensive report titled "Tirzepatide Market Forecast" offering a thorough examination and predictive insights into the Tirzepatide market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The extensive report offers a thorough examination of the market potential and market share of Tirzepatide in the therapeutics landscape for Obesity across the 7MM, spanning
SAXENDA (Liraglutide) Market Size and Share Across 7MM and Competitive Landscape by DelveInsight | Key Players - Novo Nordisk
SAXENDA (Liraglutide) Market Size and Share Across 7MM and Competitive Landscape …
DelveInsight has released a comprehensive report titled "SAXENDA (Liraglutide) Market Forecast" offering a thorough examination and predictive insights into the SAXENDA (Liraglutide) market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The extensive report offers a thorough examination of the market potential and market share of SAXENDA (Liraglutide) in the therapeutics landscape for Obesity across
High-Grade Glioma Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | BioMimetix, Oblato, PTC Therapeutics, Lee's Pharmaceutical, Nuvation Bio, Laminar Pharma, Basilea Pharma
High-Grade Glioma Pipeline Analysis Covering Clinical Trials, Emerging Therapies …
As per DelveInsight's assessment, globally, about 150+ key pharma and biotech companies are working on 150+ pipeline drugs in the High-Grade Glioma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "High-Grade Glioma Pipeline Insight, 2024" report by DelveInsight provides a comprehensive analysis
Duchenne Muscular Dystrophy (DMD) Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Capricor Therapeutics (CAP-1002), Santhera, Sarepta, Italfarmaco, FibroGen, Pfizer, Daiichi Sankyo
Duchenne Muscular Dystrophy (DMD) Pipeline Analysis Covering Clinical Trials, Em …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 75+ key pharma and biotech companies are working on 75+ pipeline drugs in the Duchenne Muscular Dystrophy therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Duchenne Muscular Dystrophy Pipeline Insight"

All 5 Releases


More Releases for Pamrevlumab

Pancreatic Cancer Market to Progress at a CAGR of 7.3 % by 2032 | DelveInsight
DelveInsight's Pancreatic Cancer Market Insights report includes a comprehensive understanding of current treatment practices, pancreatic cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan. The pancreatic cancer market is anticipated to show positive growth, mainly attributed to the increasing incident cases and also, the
Idiopathic pulmonary fibrosis market is expected to show impressive growth rate …
The Global Idiopathic Pulmonary Fibrosis Market Report published by Astute Analytica provides insight and updates about the corresponding segments in the global market for the forecast period of 2021-2027. A detailed analysis of the market dynamics is provided and comprehensive data about the structure of the industry. The Global Idiopathic Pulmonary Fibrosis Market Research Study contains exclusive insights into the market's forecast growth. Global Idiopathic Pulmonary Fibrosis Market is expected to
Idiopathic Pulmonary Fibrosis Market 2021-2030: Exceptional Business Performance …
Global Idiopathic Pulmonary Fibrosis Market Report published by Astute Analytica provides insight and updates about the corresponding segments involved in the global market for the forecast period of 2021-2030. A detailed analysis of the market dynamics is provided and comprehensive data about the structure of the industry. The Global Idiopathic Pulmonary Fibrosis Market Research Study contains exclusive insights into the market's forecast growth. Global Idiopathic Pulmonary Fibrosis Market is expected to
Idiopathic Pulmonary Fibrosis (IPF) Pipeline Insight Market Research Report 2020 …
Idiopathic Pulmonary Fibrosis (IPF) Pipeline Insight, 2020, report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered - Global coverage Idiopathic Pulmonary Fibrosis Understanding Idiopathic
Duchenne Muscular Dystrophy Treatment Market COVID-19 Pandemic Analysis, Growth …
The report "Global Duchenne Muscular Dystrophy Treatment Market By Therapeutic Approach and Treatment (Molecular-based Therapies (Mutation Suppression, and Exon Skipping), Steroid Therapy (Corticosteroids), Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Other Therapeutic Approaches and Treatment End Users), By End User (Hospitals/Clinics, Ambulatory Centers, and Other End Users), and Region - Global Forecast to 2029" Global Duchenne Muscular Dystrophy Treatment market is projected to grow from US $xx billion in 2019 to US$
Idiopathic Pulmonary Fibrosis (IPF) Market 2019 Insights: by Size, Trends, Oppor …
Idiopathic Pulmonary Fibrosis (IPF) Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of IPF in the United States, Canada, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Idiopathic Pulmonary Fibrosis from